NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2022
Historique:
revised: 16 02 2022
received: 22 10 2021
accepted: 07 03 2022
pubmed: 25 3 2022
medline: 6 5 2022
entrez: 24 3 2022
Statut: ppublish

Résumé

The aim of this study was to establish age-specific and sex-specific cut-off values for N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-troponin T) in healthy subjects and assess cardiac biomarkers as screening tools for subclinical heart failure (HF) in a general population. Altogether, 1936 participants were randomly selected from the general population Tromsø 7 study in Northern Norway. Diagnostic accuracy (sensitivity, specificity, and negative and positive predictive value) of cardiac markers for echocardiographically defined subclinical HF was evaluated. The receiver-operating characteristic analysis showed that areas under the curve were relatively low (under 0.75) for both NT-proBNP and hs-troponin T, suggesting that the diagnostic accuracy of these biomarkers for subclinical HF was not excellent, especially for mild forms of HF and younger age group 40-49 years. Sex-specific and age-specific cut-offs for hs-troponin T (99th percentiles) and NT-proBNP (97.5th percentiles) were established in healthy subjects from the same general population. The sex-specific and age-specific cut-offs for NT-proBNP had higher specificity for subclinical HF compared with the previously established single cut-off 125 pg/mL. Age-specific cut-off for hs-troponin T (18 ng/L) for men ≥60 years had also higher specificity than the single cut-off 14 ng/L. These cut-offs had high specificity, but low sensitivity, that makes hs-troponin T and NT-proBNP good biomarkers to rule in HF in case of a positive test, but not good enough to rule out all unrecognized HF due to false negative results. N-terminal pro-brain natriuretic peptide and hs-troponin T are suboptimal screening tools for subclinical HF in a general population due to low sensitivity.

Identifiants

pubmed: 35322586
doi: 10.1002/ehf2.13906
pmc: PMC9065856
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Troponin T 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1954-1962

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):613-9
pubmed: 22541282
PLoS One. 2015 Aug 05;10(8):e0134376
pubmed: 26244664
Clin Chem. 2010 Feb;56(2):254-61
pubmed: 19959623
J Card Fail. 2005 Jun;11(5 Suppl):S15-20
pubmed: 15948095
J Am Soc Echocardiogr. 2018 Nov;31(11):1209-1211
pubmed: 30269910
Eur J Heart Fail. 2013 Oct;15(10):1102-12
pubmed: 23787717
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
Int J Cardiol. 2016 Apr 15;209:26-33
pubmed: 26878470
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Clin Chem. 2019 Oct;65(10):1221-1227
pubmed: 31387884
JAMA. 2003 Jan 8;289(2):194-202
pubmed: 12517230
J Card Fail. 2009 Jun;15(5):377-84
pubmed: 19477397
Br J Gen Pract. 2006 May;56(526):327-33
pubmed: 16638247
Clin Chem Lab Med. 2013 May;51(5):1125-33
pubmed: 23183754
JAMA Intern Med. 2013 Sep 23;173(17):1592-8
pubmed: 23877591
Eur J Heart Fail. 2016 Nov;18(11):1342-1350
pubmed: 27813304
Am J Med. 2015 Mar;128(3):276-82
pubmed: 25447612
J Card Fail. 2016 Jan;22(1):17-23
pubmed: 26093333
Int J Cardiol. 2010 Apr 30;140(3):336-43
pubmed: 19147239
Arch Gerontol Geriatr. 2016 Jul-Aug;65:111-5
pubmed: 27017416
Arch Intern Med. 2011 Jun 27;171(12):1082-7
pubmed: 21709107
Clin Chim Acta. 2011 Apr 11;412(9-10):748-54
pubmed: 21219893
N Engl J Med. 2004 Feb 12;350(7):655-63
pubmed: 14960742
Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):296-300
pubmed: 25991044
Heart. 2007 Sep;93(9):1137-46
pubmed: 17699180
Eur J Heart Fail. 2005 Jun;7(4):537-41
pubmed: 15921792
Eur Heart J. 2012 Jul;33(14):1787-847
pubmed: 22611136
Int J Cardiol. 2013 Aug 20;167(4):1423-9
pubmed: 22560907
ESC Heart Fail. 2022 Jun;9(3):1954-1962
pubmed: 35322586
N Engl J Med. 2006 Jul 20;355(3):251-9
pubmed: 16855265
Circ Heart Fail. 2012 May 1;5(3):303-6
pubmed: 22589364

Auteurs

Maria Averina (M)

Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, 9038, Norway.
Department of Community Medicine, UiT the Arctic University of Norway, Tromsø, Norway.

Michael Stylidis (M)

Department of Community Medicine, UiT the Arctic University of Norway, Tromsø, Norway.

Jan Brox (J)

Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, 9038, Norway.

Henrik Schirmer (H)

Department of Cardiology, Akershus University Hospital, Lørenskog, Norway.
Institute of Clinical Medicine, Cardiovascular Research Group, Campus Ahus, University of Oslo, Oslo, Norway.
Institute of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH